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Common versus uncommon causes
of dementia
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ABSTRACT
When patients present with a dementia syndrome at a young age, the
experienced clinician will automatically include uncommon dementias in the
diagnostic considerations, as familial uncommon dementias due to genetic
mutations frequently present as early-onset dementias. This paper highlights
why uncommon dementias due to geneticmutations, althoughmarginal in terms
of prevalence numbers in the total population, are of significance in the quest to
unravel the underlying cause of common dementias such as Alzheimer’s disease
(AD), dementia with Lewy bodies (DLB), frontotemporal dementias (FTD)
and vascular dementia (VaD).
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Introduction
Common versus uncommon: some thoughts about terminology
When acquiring knowledge about dementia, the categories of common and
uncommon causes of dementia are soon apparent. Alzheimer’s disease (AD)
and vascular dementia (VaD) are usually described as the two most common
causes of dementia worldwide, with some variation in prevalence between the two
depending on ethnic background. Uncommon dementias often appear clinically
as part of a syndrome of a complex neurological or systemic disorder and the
challenge is to identify them correctly, if possible, because curative treatment
might be available in the rare subgroup of reversible dementia syndromes. This
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is often the case in acquired syndromes, such as those due to infections, but also
occurs with inherited conditions, such as Wilson’s disease.
A common dementia, such as AD (50–60% of all dementia cases), shows
similarities with other common diseases, such as type 2 diabetes mellitus
or hypertension. These diseases tend to show an increase in incidence and
prevalence with age and the underlying disease processes and their causes
are often considered to be multifactorial, involving interplay between several
genes and environmental factors. Patients with the same disease phenotype can
present with a variety of different risk-factor combinations, including different
combination sets of predisposing genes. How these various risk factors interact
and influence each other’s expression remains largely unknown.
As the most frequent types of dementia can be considered complex genetic
diseases, it may be surprising that knowledge about the underlying causes of
some of the rare causes of dementia, although much less prevalent, is more
advanced, especially in monogenic disorders such as Huntington dementia. It is
possible, therefore, that we will learn more about the common types of dementia
by studying its least frequent causes. In fact, much of what we now know about
AD has arisen from the study of its uncommon causes, such as familial AD
associated with autosomal dominant inheritance.
Genetic information on rare neurodegenerative dementias applied
to common dementias
Familial Alzheimer’s disease (FAD)
Familial AD (FAD) is rare, accounting for up to 5% of all cases of AD
(Cummings and Cole, 2002). To date, mutations to three genes, the amyloid
precursor protein (APP) on chromosome 21, the presenilin 1 (PS1) on
chromosome 14, and the presenilin 2 (PS2) on chromosome 1, have been
identified as causing FAD with a penetrance of more than 85% (St. George-
Hyslop, 2000). All these mutations seem to result in the overproduction of
the β-amyloid protein (Aβ), which is generated by cleavage of the APP by the
enzymes β- and γ-secretase. The soluble oligomeric form of Aβ is thought to
be the major toxic form of Aβ, causing, initiating or contributing to synaptic
degeneration and ultimately nerve cell death. The soluble form of Aβ eventually
forms fibrils in the extracellular space and is deposited as amyloid plaques,
one of the neuropathological hallmarks of familial and sporadic AD. These Aβ
fibrils are thought to play a key role in neuroinflammation. This knowledge of
Aβ, the development of amyloid plaques and the β-amyloid cascade hypothesis
(Hardy and Higgins, 1992), had its origins in the investigation of a very small
number of families with FAD. The identification of the relevant genes, as well as
their pathogenic mutations, enabled scientists to develop laboratory and animal
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models of the illness. In other words, our current understanding of the common
sporadic form of AD is heavily based on models generated through the study of
rare familial cases of AD. This knowledge should contribute to the development
of effective and specific treatments for AD in the near future.
Dementia with Lewy bodies (DLB)
DLB was described systematically in the 1980s as a clinically distinguishable
dementia syndrome (Kosaka et al., 1980). Autopsy studies diagnosed DLB in
15–20%of patients with dementia (McKeith, 2002); however, the discrimination
from AD pathology is controversial and led to the description of subtypes such as
“DLB with senile plaques,” “pure DLB” and “plaque-only AD with or without
Lewy bodies” (Ince et al., 1998). There is also clinical overlap of symptoms
with other dementias such as AD, Parkinson’s disease (PD), PD with dementia
(PDD) and progressive supranuclear palsy (PSP) (Graeber and Mu¨ller, 2003).
Thirty-five percent of patients with AD, for example, develop extrapyramidal
signs and up to 40% of patients with PD develop cognitive decline (Galvin et al.,
2001).
DLB is characterized by visual hallucinations, fluctuations of cognitive
function, frequent falls, a sensitivity to the extrapyramidal side-effects of
antipsychotic medications, and parkinsonism (McKeith et al., 1996). Like its
more common neurodegenerative counterpart AD, DLB is considered to be a
“complex disorder” (Graeber and Mu¨ller, 2003) and, as is the case for AD,
the study of uncommon familial cases of DLB unravels some of its underlying
genetic pathological mechanisms.
A few families with an autosomal-dominant inheritance pattern, often with
low penetrance, have been described (Brett et al., 2002; Galvin et al., 2002). In
a recently described Spanish family with familial DLB, the causative mutation,
E46K in the α-synuclein gene on chromosome 4, was identified (Zarranz et al.,
2004). This mutation seems to interfere with the normal function of the
presynaptic α-synuclein protein. Misfolded α-synuclein is the main component
of the Lewy bodies, which in DLB are usually located in the substantia nigra,
basal nucleus of Meynert, locus coeruleus and gray matter. Its function is not
yet fully understood, but it might be involved in lipid binding and play a role
in the regulation of dopamine release at the presynaptic terminal (Galvin et al.,
2001). As a result of these investigations, and those of closely related forms of
PD, DLB is now described as synucleinopathy, more closely related to PD than
to AD pathology.
Frontotemporal dementias or degenerations (FTD)
The thirdmost prevalent form of neurodegenerative dementias following AD and
DLB comprises the frontotemporal dementias or degenerations (FTD). This
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group includes Pick’s disease, FTD without specific neuropathological features,
corticobasal degeneration, dementias with parkinsonism linked to chromosome
17mutations, and dementias associated withmotor neuron disease (Lovestone et
al., 2002). The various types of FTDhave in common a progressive degeneration
of the frontal and/or temporal lobes. While FTD are considered less frequent
than AD, a lack of epidemiological data, together with confusion regarding
diagnostic criteria, results in uncertainty regarding its true prevalence and
incidence. FTD typically has its onset before age 65 years. Recent prevalence
studies reported a mean age at onset of 52.8 ± 8.7 years in the U.K. and 57.9 ±
9.0 in the Netherlands (Ratnaavalli et al., 2002; Rosso et al., 2003). Prevalence
data vary depending on the method and criteria used. A recent study from the
province of Zuid-Holland in the Netherlands reported prevalence rates of 3.6,
9.4 and 3.8 per 100000 at ages 50–59, 60–69 and 70–79 years, respectively
(Rosso et al., 2003). A study from the U.K. found a prevalence of 15 cases per
100000 at age 45–64 years (Ratnaavalli et al., 2002). Compared to AD and
DLB, the percentage of familial cases is higher in FTD. Rosso et al. (2003)
reported in a data set of 345 FTD patients the presence of mutations of the
tau gene on chromosome 17 in 32% of patients with other affected first-degree
family members, and 43% for all patients with FTD.
Stanford et al. (2004) found a tau gene mutation in 25% of patients with
familial FTD, but only in 4% of those without a positive family history. The
clinical phenotype of tauopathies can vary considerably within the same family
(van Swieten et al., 2004). More than 25 different mutations in the tau gene have
been reported and a common pathological feature for most of these “mutation-
cases” of FTD is the occurrence of fibrillar tau-based pathology in the neurons
(Pickering-Brown, 2004). This contributed to the hypothesis that the deposition
of tau could be the core pathological process leading to clinical symptoms in
tauopathies (Spillantini et al., 1998). However, Stanford et al. (2004) recently
reported the presence of tau mutations without evidence of accumulation of
insoluble tau or tau-based neuronal inclusions. There are also FTD families that
show a positive linkage to chromosome 17 without detection of a specific tau
mutation and without the typical fibrillar tau pathology of the “mutation-cases.”
The implications of uncommon hereditary forms on sporadic forms
of vascular dementia
Cerebral autosomal dominant arteriopathy with subcortical infarcts
and leukoencephalopathy (CADASIL)
Strokes represent the pathological basis of VaD. A very small group of VaD cases
are due to underlying genetic conditions that increase the risk of strokes. This is
a very variable group of conditions including hemoglobinopathies, coagulation
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disorders, mitochondrial disorders, connective tissue diseases and angiopathies,
among others, which can trigger small- and large-artery disease, embolic or
hemorrhagic strokes (Schmidt and Schmidt, 2002).
CADASIL is an uncommon inherited nonamyloid systemic angiopathy
caused by mutations in the notch 3 gene on chromosome 19. It has been
only recently identified as an uncommon cause of familial VaD, with some 100
families identified worldwide (Dichgans, 2004; Tournier-Lasserve et al., 1993).
The clinical phenotype is highly variable, with age at onset as early as the twenties
or as late as the seventies, and includes migraine with aura, epileptic seizures,
transient ischemic attacks (TIAs), strokes and vascular cognitive impairment
and dementia (Chabriat et al., 1995; Dichgans et al., 1998). Age at onset does
not correlate with progression or severity of illness and mean age of death is
around age 60 years (Desmond et al., 1999). Cognitive impairment is reported
in 60% of cases, with two-thirds reaching the clinical threshold of a dementia
syndrome at age 65 years. The dementia syndrome is mostly of a subcortical
type (Dichgans et al., 1998). But how do mutations in notch 3 cause angiopathy
and how does this lead to VaD? The missense mutations lead to a gain or loss
of cysteine residues in the extracellular portion of the transmembrane notch
3 protein. The particular part of the protein affected is called the epidermal
growth factor (EFG)-like domain (Dichgans, 2004). The angiopathy affects
the cerebral small vessels and causes significant damage to the media and
endothelium of smooth muscle cells. One hypothesis is that this angiopathy
leads to a reduced ability of the blood vessels to autoregulate and thus results
in reduced cerebral perfusion (Singhal et al., 2004). The majority of genotype–
phenotype correlation studies in CADASIL could not find any impact on the
site of the mutation on the phenotype. One possible explanation is that lacunar
strokes might develop because of a sudden disruption of perfusion in the blood
vessel, which requires, in addition to the genotype, the presence of additional
modulating factors to exacerbate the situation (Singhal et al., 2004). One of
these environmental factors has been identified as smoking in a recent genotype–
phenotype study with 65 families with CADASIL from the U.K. (Singhal et al.,
2004). The authors suggested that smoking could adversely affect vasomotor
function (Iida et al., 1998) and induce a prothrombotic state (Hioki et al., 2001)
in CADASIL patients.
Conclusion
Why are findings of the underlying causes of uncommon dementias relevant
beyond the specific rare syndrome? One reason is that they might help us
to identify clinically healthy family members at high genetic risk in these
rare families with hereditary uncommon dementias. The assessment of these
S32 N. T. Lautenschlager and R. N. Martins
“carrier” family members prior to clinical diagnosis helps us to understand
the temporal relationship of the onset of clinical symptoms, which can also
contribute to improving the early diagnosis of common dementias. Geschwind
et al. (2001) reported that clinically “presymptomatic” carriers of families of
familial chromosome 17 FTD showed significant executive dysfunctions decades
before expected clinical onset. Findings such as these challenge disease-onset
hypotheses and suggest that carriers might be already born with certain altered
brain function. If this is true, even the use of the terminology “dementia,” defined
as acquired cognitive impairment, might need to be reviewed.
Modern drug development research frequently takes its origin from
discoveries of pathological mechanisms present in rare-mutation families with
AD or FTD with the aim of developing medications that might be of benefit
to patients with AD or FTD in general. For example, the recent discovery
that inhibitors to the glycogen-synthase kinase-3β (GSK-3β), the enzyme that
mediates the phosphorylation of the tau protein, can effectively reduce the
phosphorylation of tau (Mudher et al., 2004) might have a significant impact
on drug development for treating tauopathies. This discovery is particularly
impressive in that one of the substances effectively inhibiting GSK-3β is lithium
chloride. Therefore, changes to the underlying hypotheses of pathological
processes might also influence future treatment options for the large number
of patients with common dementias (Pickering-Brown, 2004).
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